Literature DB >> 23583082

Synthesis, metabolite analysis, and in vivo evaluation of [(11)C]irinotecan as a novel positron emission tomography (PET) probe.

Kazunori Kawamura1, Hiroki Hashimoto, Masanao Ogawa, Joji Yui, Hidekatsu Wakizaka, Tomoteru Yamasaki, Akiko Hatori, Lin Xie, Katushi Kumata, Masayuki Fujinaga, Ming-Rong Zhang.   

Abstract

INTRODUCTION: Irinotecan is a semisynthetic derivative of camptothecin that exerts potent antitumor activity by inhibiting topoisomerase I. Despite much research into the complex pharmacokinetic profile and pharmacodynamic effects of irinotecan, unpredictable and severe side effects are still commonly observed. In this study, we synthesized [(11)C]irinotecan as a positron emission tomography (PET) probe, performed the metabolite analysis, and evaluated the biodistribution and kinetics of [(11)C]irinotecan using small animal PET.
METHODS: [(11)C]Irinotecan was synthesized by two routes using [(11)C]phosgene and [(11)C]carbon dioxide fixation. Metabolites in the plasma of mice following injection of [(11)C] irinotecan were investigated using a combination of column-switching high-performance liquid chromatography (HPLC) and on-line solid-phase extraction (SPE). Whole-body PET studies were conducted in wild-type mice and P-glycoprotein and breast cancer resistance protein (Pgp/Bcrp) knockout mice.
RESULTS: [(11)C]Irinotecan was successfully synthesized by the two abovementioned routes. Decay-corrected radiochemical yields based on [(11)C]carbon dioxide using [(11)C]phosgene and [(11)C]carbon dioxide fixation were 8.8 ± 2.0% (n=8) and 16.9 ± 2.9 % (n=5), respectively. Metabolite analysis of the plasma of mice following injection of [(11)C]irinotecan was successfully performed using the column-switching HPLC and on-line SPE combination resulting in greater than 87 % recovery of radioactivity from HPLC. In the PET study in mice, the radioactivity levels in the brain, liver, and small intestine were slightly increased by inhibition of the Pgp/Bcrp function for more than 30 min after [(11)C]irinotecan injection. This result demonstrated that in vivo behavior of [(11)C] irinotecan and radioactive metabolites are influenced by the Pgp/Bcrp function.
CONCLUSION: PET studies using [(11)C]irinotecan combined with metabolite analysis may be a useful tool for evaluating irinotecan pharmacokinetics and toxicity.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23583082     DOI: 10.1016/j.nucmedbio.2013.03.004

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  5 in total

1.  Change in the Binding of [11C]BU99008 to Imidazoline I2 Receptor Using Brain PET in Zucker Rats.

Authors:  Kazunori Kawamura; Tomoteru Yamasaki; Yiding Zhang; Hidekatsu Wakizaka; Akiko Hatori; Lin Xie; Masayuki Fujinaga; Ming-Rong Zhang
Journal:  Mol Imaging Biol       Date:  2019-02       Impact factor: 3.488

Review 2.  (11)C[double bond, length as m-dash]O bonds made easily for positron emission tomography radiopharmaceuticals.

Authors:  Benjamin H Rotstein; Steven H Liang; Michael S Placzek; Jacob M Hooker; Antony D Gee; Frédéric Dollé; Alan A Wilson; Neil Vasdev
Journal:  Chem Soc Rev       Date:  2016-08-22       Impact factor: 54.564

Review 3.  11CO2 fixation: a renaissance in PET radiochemistry.

Authors:  Benjamin H Rotstein; Steven H Liang; Jason P Holland; Thomas Lee Collier; Jacob M Hooker; Alan A Wilson; Neil Vasdev
Journal:  Chem Commun (Camb)       Date:  2013-05-14       Impact factor: 6.222

4.  MBL-II-141, a chromone derivative, enhances irinotecan (CPT-11) anticancer efficiency in ABCG2-positive xenografts.

Authors:  Léa Payen; Mylène Honorat; Jérôme Guitton; Charlotte Gauthier; Charlotte Bouard; Florine Lecerf-Schmidt; Basile Peres; Raphaël Terreux; Héloïse Gervot; Catherine Rioufol; Ahcène Boumendjel; Alain Puisieux; Attilio Di Pietro
Journal:  Oncotarget       Date:  2014-12-15

5.  Radiosynthesis and in vivo evaluation of 11C-labeled BMS-193885 and its desmethyl analog as PET tracers for neuropeptide Y1 receptors.

Authors:  Kazunori Kawamura; Wakana Mori; Masayuki Fujinaga; Tomoteru Yamasaki; Yiding Zhang; Hidekatsu Wakizaka; Akiko Hatori; Lin Xie; Katsushi Kumata; Takayuki Ohkubo; Yusuke Kurihara; Masanao Ogawa; Nobuki Nengaki; Ming-Rong Zhang
Journal:  EJNMMI Radiopharm Chem       Date:  2019-02-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.